Singapore, June 12 -- Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with South Korea's Samil Pharmaceuticals, for exclusive rights to the commercialisation of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in Vietnam.

Samil is one of the most prominent Korean manufacturers of pharmaceutical products across multiple therapeutic areas, with a core specialisation and focus on ophthalmic medicines, and having long-standing partnerships with global players such as Samsung, Abbvie, Nicox, and Thea. The licensing agreement includes upfront payment, regulatory milestones, and royalties, throu...